Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24137579)

  • 1. An evaluation of the predictive value of mid-treatment 18F-FDG-PET/CT scans in pediatric lymphomas and undefined criteria of abnormality in quantitative analysis.
    Zhu HJ; Halkar R; Alavi A; Goris ML
    Hell J Nucl Med; 2013; 16(3):169-74. PubMed ID: 24137579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
    Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
    J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for N2 metastasis in patients with non-small-cell lung cancer: multivariate analyses of 18F-FDG PET/CT data.
    Su M; Li Y; Li F; Li L; Tian R
    Nucl Med Commun; 2014 Sep; 35(9):916-21. PubMed ID: 24785010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET-CT in the management of primary breast lymphoma.
    Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
    Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
    Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA
    Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
    Metser U; Miller E; Lerman H; Even-Sapir E
    AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL; Jones RJ; Wahl RL
    J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
    Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
    Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma.
    Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S
    Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
    Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
    J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary.
    Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C
    J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid incidentalomas on FDG PET/CT in patients with non-thyroid cancer - a large retrospective monocentric study.
    Kim H; Kim SJ; Kim IJ; Kim K
    Onkologie; 2013; 36(5):260-4. PubMed ID: 23689220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.